Galectin Therapeutics (GALT) Operating Expenses (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Operating Expenses of $4.1 million for Q1 2026, down 48.37% year-over-year from $7.9 million in Q1 2025, and up 21.16% quarter-over-quarter from $3.4 million in Q4 2025.
Galectin Therapeutics (GALT) Operating Expenses (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 48.37% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $16.3 million (down 60.02% YoY), while the FY2025 annual figure was $20.1 million, down 52.67% from the prior year.
- Operating Expenses for Q1 2026 stood at $4.1 million, up from $3.4 million in the prior quarter.
- The five-year high for Operating Expenses was $12.4 million in Q4 2024, with the low at $3.4 million in Q4 2025.
- The 5-year median for Operating Expenses is $9.2 million (2023), against an average of $8.4 million.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 57.27% in 2022, then sank 72.92% in 2025.
- Galectin Therapeutics' Operating Expenses stood at $10.6 million in 2022, then decreased by 10.08% to $9.6 million in 2023, then climbed by 29.99% to $12.4 million in 2024, then tumbled by 72.92% to $3.4 million in 2025, then advanced by 21.16% to $4.1 million in 2026.
- Business Quant data shows GALT's Operating Expenses at $4.1 million in Q1 2026, $3.4 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.08 Mn |
| Dec 31, 2025 | 3.37 Mn |
| Sep 30, 2025 | 4.20 Mn |
| Jun 30, 2025 | 4.63 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | 12.43 Mn |
| Sep 30, 2024 | 9.07 Mn |
| Jun 30, 2024 | 11.29 Mn |
| Mar 31, 2024 | 9.65 Mn |
| Dec 31, 2023 | 9.56 Mn |
| Sep 30, 2023 | 9.17 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Mar 31, 2023 | 10.34 Mn |
| Dec 31, 2022 | 10.63 Mn |
| Sep 30, 2022 | 8.12 Mn |
| Jun 30, 2022 | 9.66 Mn |
| Mar 31, 2022 | 9.94 Mn |
| Dec 31, 2021 | 7.43 Mn |
| Sep 30, 2021 | 8.24 Mn |
| Jun 30, 2021 | 8.19 Mn |